This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
Introduction
The benefits from large-scale use of potent immunomodulatory therapy for relapse suppression in multiple sclerosis are accompanied by an array of very real general and treatment-specific risks.
The use of the anti-CD52 humanised monoclonal antibody Alemtuzumab comes with a broad awareness and vigilance for wellrecognised and largely delayed autoimmune complications (1) (2) (3) (4) (5) (6) and the more immediate, infusion-related events that can be serious in approximately 3% of cases (2, 4, 7) .
To date there have also been 4 reported cases of listeriosis which have resulted in syndromes of acute meningitis (8, 9) or listeriosis (10) with sepsis specifically during the broad immune-deplete phase in the daysweeks following completion of Alemtuzumab infusion cycles (10) (11) (12) (13) . Although approximately 9200 patients have now received this therapy for the indication of multiple sclerosis (14) suggesting this occurrence is relatively rare. A high index of suspicion and low threshold for intervention is required for listeriosis as its presentation may be clouded by common symptoms associated with Alemtuzumab. Furthermore, effective treatment is readily available but risk of immediate mortality is high.
We present the first case of mortality due to confirmed listeriosis which arose after completion of the first Alemtuzumab infusion cycle and discuss some important considerations. Electroencephalography demonstrated a globally isoelectric recording and a full dependence on ventilator support ensued with loss of self-initiated respirations.
Case Description
Repeat cranial CT imaging with angiographic sequences revealed severe global cerebral oedema with worsening cisternal effacement and generally poor angiographic flow and incipient herniation despite adequate positioning of the external ventricular drain [see figure 1b] .
PCR on the CSF yielded a positive result for Listeria monocytogenes. Despite resolution of pyrexia and improving inflammatory indices a diagnosis of brain death was recorded at 60 hours following admission. Cultures of blood and CSF later supported the diagnosis of listeriosis.
Discussion
Although the risk of opportunistic and atypical infections in the context of immunosuppression is familiar, the particular vulnerability to listeriosis in the acute phase following Alemutuzumab administration is not broadly appreciated.
In this case as with others in the literature(10-13), the patient did not have clear exposure to foodstuffs classically associated with heightened listeria risk. The patient had been concordant with our local dietary guidelines (first two weeks post Alemtuzumab commencement) formally issued to patients undergoing Alemtuzumab therapy. At the time there was no mandatory SPC advice in Europe to avoid such foodstuffs (18) . This has since changed as of June 2016 (17). Similarly with the other cases the timing appears, at least so far, specific to the period of maximum suppression of lymphocyte counts following the anti-CD52 effect (19).
Rau et al. (10) suggest that the listeriosis arising in these patients represents a reactivation of latent infection from possible reservoirs in the gallbladder or bone marrow tissues due to loss of the normal defence afforded by CD8 T cell cytotoxic effects, which are singularly important in host repulsion of listeria intracellular bacteria (10) . As such, the required duration of dietary abstinence becomes far less clear.
This may be particularly important in patients exposed to prior immunomodulatory therapies.
The typical CSF picture associated with listeria is one of marked neutrophilic pleocytosis, elevated protein and, where sampled, raised lactate. This is seen in 77% of cases (20) , however this pattern may be absent and in this context of immunoparesis, the isolated hypoglycorrachia as seen here may be the sole abnormality in addition to raised intracranial pressure (10) .
It is recognised that while listerial meningitis produces the full constellation of febrile illness, with meningism, neurological deficit and sepsis syndrome, this often develops subacutely, with gastroenteritis and nonspecific malaise dominating initially (10, 20) . Timely diagnosis is further hindered by the prevalence, as seen in both trials and clinical practice, of near ubiquitous malaise, headache symptoms and low grade pyrexia with Alemtuzumab administration (2, 4, 11,  21 ).
The timing of listeriosis here in relation to therapy, as with the other reported cases, strongly suggests a causal relationship. However the timing and nature of prior disease modifying therapy is also an important consideration.
The decision to escalate from dimethyl fumarate to Alemtuzumab was stimulated by further clinical relapse activity whilst on the former.
On the basis of published pharmacokinetic data for dimethyl fumarate (EMA Summary of Product Characteristics) a month-long period of washout was undertaken prior to Alemtuzumab initiation. The haematologic profile at baseline did demonstrate a very mild lymphopenia that was considered acceptable.
The time spent off therapy was considered to pose significant risk of further relapses and the hazards of irreversible damage or limiting function inherent to them. The phenomenon of 'rebound relapse' after disease modifying therapy discontinuation, or at least return to baseline relapse rates is well described (22) (23) (24) .
Other reported cases of listeriosis/listeria meningitis have similarly affected individuals completing Alemtuzumab administration after experiencing relapsing disease uncontrolled by a range of licensed therapies with varying modes of action (10) (11) (12) (13) .
With the growing move toward 'No Evidence of Disease Activity' as a treatment target and with no currently available therapy achieving this in more than 50% of patients over an initial 2 year period even with Alemtuzumab (25, 26) a growing number of patients will be deemed to require escalation. Despite the vast number of permutations of treatment combinations and their timings, MS physicians currently have comparatively little non-trial data on the risks thereof to guide informed decision making. Caution is therefore mandatory.
With respect to mitigating future risks of listeriosis with Alemtuzumab, dietary guidance alone may be insufficient and CSF analysis on all patients with headache is impractical and not without its own risk. We therefore advocate a high index of suspicion and low threshold for empirical therapy in all those with progressive systemic symptoms or headache, or fever in the days and weeks following Alemtuzumab administration to avoid further mortality from listeriosis in this context.
Alternatively, prophylactic cover of listeriosis using antibiotics such as Co-Trimoxazole, as used in other specialist areas using higher dose Alemtuzumab (27-29) could be considered. Although Co-Trimoxazole in itself may pose adverse reactions.
Conclusion
Alemtuzumab therapy appears to confer a specific vulnerability to Listeria monocytogenes infection. This led to mortality from a very rapidly progressive meningoencephalitis following otherwise routine administration in a typical case of multiple sclerosis. Preceding disease modifying therapy may modify risk in a currently unquantified manner and high vigilance for this complication is needed. The speed of onset in this case should raise awareness of the need to see such patients without delay to minimise risk.
